The FDA was supposed to be a boring part of Trump's health machinery. Instead, it has become a political pressure cooker where surprise firings, policy reversals, and industry uncertainty have become the norm. Late Friday, the agency's commissioner Marty Makary appeared to dodge a bullet after reports suggested his ouster was imminent.
The stakes are enormous. The FDA regulates roughly one-fifth of the American economy, giving it outsized influence over drug approvals, medical devices, and food safety. Instability at the top translates directly into disruption across entire industries.
Makary, a Johns Hopkins physician and researcher, has overseen a turbulent tenure marked by battles over abortion pills, flavored vapes, vaccine policy, and drugs for rare diseases. He has also pushed initiatives to accelerate drug approvals and reduce regulatory burdens that are still in motion, regardless of his future at the agency.
When asked Friday about the firing reports, Trump offered a classic non-answer: "I've been reading about it, but I know nothing about it." The White House remained silent on Makary's status. A White House official told Politico that the push for his removal came from senior Health and Human Services leaders, not from Trump directly.
But here is the catch: Trump has a documented pattern of changing his mind dramatically and quickly. Makary's apparent reprieve offers no guarantee of permanence. A Senate Appropriations Committee hearing on Wednesday, where Makary is scheduled to testify about the FDA's 2027 budget, could shift the conversation once again.
If Makary does leave, internal candidates are already being discussed as replacements. Kyle Diamantas, the deputy commissioner for food, has been mentioned. There is also speculation that Trump could tap a veteran from his first administration, with former FDA Commissioner Stephen Hahn and Brett Giroir, who briefly served as acting commissioner, among those floated.
Industry analysts expect the next commissioner to be less volatile and more pro-business than Makary. "We expect the White House to nominate a less disruptive, pro-industry commissioner, consistent with other recent steps the administration has taken to moderate the agency," Capstone analyst Will Humphrey wrote.
The pharmaceutical industry, both large drugmakers and smaller biotechs, would likely welcome the predictability. But deeper problems persist. The FDA's workforce has been gutted by attrition since Trump took office. While Makary announced plans this month to hire 3,000 additional scientists, data shows that staffing at the agency's biologics and drug evaluation centers each dropped more than 19%, with critical vacancies in director and deputy director roles.
High-stakes decisions loom. The agency must still rule on experimental cancer and ADHD treatments, rare disease drugs, and Moderna's mRNA flu shot, which the FDA initially refused to evaluate before reversing course. A new commissioner could take different positions on these issues, creating further uncertainty.
Even if Makary hangs on or is replaced, the underlying chaos will not disappear overnight. The question is whether the next leader can stabilize an agency that has become a political football rather than a neutral arbiter of drug safety and efficacy.
Author James Rodriguez: "The FDA's credibility problem runs deeper than one commissioner's job security, and no personnel shakeup will fix it overnight."
Comments